192 related articles for article (PubMed ID: 31743846)
1. Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis.
Lau AY; Lui GCY; Chan KP; Au C; Mok VCT; Ziemssen T
Mult Scler Relat Disord; 2020 Feb; 38():101503. PubMed ID: 31743846
[TBL] [Abstract][Full Text] [Related]
2. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A
Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423
[TBL] [Abstract][Full Text] [Related]
3. Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis.
Matraiah EH; Olisaka N; Philipos M; Walbaum D; Dospinescu P; Fluck N; Basu N; Kidder D
Clin Rheumatol; 2018 Jul; 37(7):1991-1996. PubMed ID: 29808456
[TBL] [Abstract][Full Text] [Related]
4. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
Whiteside D; Barth S; Datta A; Trip SA
Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
[TBL] [Abstract][Full Text] [Related]
5. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.
Holmøy T; Fevang B; Olsen DB; Spigset O; Bø L
BMC Res Notes; 2019 Aug; 12(1):497. PubMed ID: 31405369
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
[TBL] [Abstract][Full Text] [Related]
7. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
[TBL] [Abstract][Full Text] [Related]
8. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
[TBL] [Abstract][Full Text] [Related]
9. Clinical observation during alemtuzumab administration.
Allen CM; Feng JJ; Willis MD; McGinley M; Ontaneda D; Tallantyre EC; Evangelou N
Mult Scler Relat Disord; 2020 Jan; 37():101412. PubMed ID: 32172992
[No Abstract] [Full Text] [Related]
10. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
[TBL] [Abstract][Full Text] [Related]
11. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
[TBL] [Abstract][Full Text] [Related]
12. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
Romba MC; Newsome SD; McArthur JC
Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
[TBL] [Abstract][Full Text] [Related]
13. Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors.
Ryan CE; Cheng MP; Issa NC; Brown JR; Davids MS
Blood Adv; 2020 Apr; 4(7):1458-1463. PubMed ID: 32282880
[TBL] [Abstract][Full Text] [Related]
14. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
Russo CV; Saccà F; Paternoster M; Buonomo AR; Gentile I; Scotto R; Brescia Morra V; Mansueto G
Mult Scler; 2020 Jan; 26(1):123-126. PubMed ID: 30882274
[No Abstract] [Full Text] [Related]
15. Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration.
Hoffman BM; Zeid NA; Alam U; Caress JB
Mult Scler Relat Disord; 2019 Jan; 27():131-132. PubMed ID: 30384197
[TBL] [Abstract][Full Text] [Related]
16. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
Ahrabian D; Neill L; Bell R; Leary SM
Mult Scler; 2020 May; 26(6):735-737. PubMed ID: 32298216
[TBL] [Abstract][Full Text] [Related]
17. Low incidence of Pneumocystis jirovecii pneumonia in an unprophylaxed liver transplant cohort.
Sarwar S; Carey B; Hegarty JE; McCormick PA
Transpl Infect Dis; 2013 Oct; 15(5):510-5. PubMed ID: 23930824
[TBL] [Abstract][Full Text] [Related]
18. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
Schmajuk G; Jafri K; Evans M; Shiboski S; Gianfrancesco M; Izadi Z; Patterson SL; Aggarwal I; Sarkar U; Dudley RA; Yazdany J
Semin Arthritis Rheum; 2019 Jun; 48(6):1087-1092. PubMed ID: 30449650
[TBL] [Abstract][Full Text] [Related]
19. A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS.
Rolfes L; Pfeuffer S; Ruck T; Windhagen S; Oschlies I; Pavenstädt HJ; Angenendt L; Wiendl H; Krämer J; Meuth SG
Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31704887
[No Abstract] [Full Text] [Related]
20. Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
Romero A; Midaglia L; Salcedo MT; Viladomiu L; Guillén E; Bajaña I; Escolà-Vergé L; Tintoré M; Montalban X; Len O
Mult Scler Relat Disord; 2020 May; 40():101973. PubMed ID: 32028116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]